Lenvima (lenvatinib) — United Healthcare
Cutaneous melanoma
Preferred products
- Keytruda (pembrolizumab)
Initial criteria
- Diagnosis of cutaneous melanoma
- Disease is unresectable OR metastatic
- Used in combination with Keytruda (pembrolizumab)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Lenvima therapy
- Used in combination with Keytruda (pembrolizumab)
Approval duration
12 months